Loading…
← CockpitCompetitor Analysis › 300244.SZ Dian Diagnostics Group Co. Ltd. Class AOpen in the cockpit ↗

Dian Diagnostics Group Co. Ltd. Class A300244.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical/Nursing Services

Major Chinese independent clinical laboratory chain providing outsourced diagnostic testing to hospitals.

≈ A Chinese LabCorp/Quest DiagnosticsMomentum strong 77
Mkt cap
$1.70B
US dollars, full cap
Free float
87%
of shares outstanding
$/day
$157M
20-day average traded
Fwd P/E
21.8×
forward earnings
ROIC−WACC
+0.4 pp
WACC 8.6%
Hurdle
+1 pp
Req g minus delivered
Next earnings
142 days
9 Apr 2027
Close · CNYCN¥18.88
1D-1.9%
1W-13.8%
1M-13.3%
3M-10.7%
6M+0.8%
YTD+19.1%
1Y+15.1%
ATR %6.5%
52w lowhigh43.3% off high

What Dian Diagnostics does

Major Chinese independent clinical laboratory chain providing outsourced diagnostic testing to hospitals.

Is paid per test: hospitals send samples to its labs, or have it run their lab, and it bills the hospital or health authority, so income tracks testing volumes and local price cuts. COVID testing was a large one-time boost to volumes in 2020 to 2022, which later receded.

In one line: A Chinese LabCorp/Quest Diagnostics.

Products and services

  • Clinical laboratory testing
  • Molecular/genetic testing
  • Pathology services

Customers

  • Hospitals (outsourced testing)
  • Clinics

Where it sits in the supply chain

  • Health Care
  • Diagnostic services
  • Independent clinical laboratory (ICL)…

What could go right

  • Outsourced hospital lab-testing growth

What could go wrong

  • Hospital reimbursement/pricing pressure

Moat: narrow (scale, installed base). National lab network and hospital relationships are costly for smaller labs to replicate.

Headquarters: Hangzhou, Zhejiang, China · Founded: 1996 · Employees: 7,462

Named competitors

Dian Diagnostics at a glance

Size Dian Diagnostics (300244.SZ) is a China Health Care company (Medical/Nursing Services) with a market value of $1.70B, the 1348th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.88 on 18 Nov 2026.

Performance Over six months the shares gained 0.8%, against +19.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue fell 5.3% over the last twelve months (peer median +9.2%); the operating margin is 8.6% (peer median 3.2%).

Valuation It trades at 21.8× forward earnings against a peer median of 33.8× (6th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.4 points above its cost of capital (8.6% WACC).

Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 120300244.SZ 101
Six months, rebased to 100: Dian Diagnostics against the median of its 20 peers (local-currency closes).

Dian Diagnostics financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥9.94BCN¥10.1BCN¥12.2BCN¥13.4BCN¥20.2B
Revenue growth—-17%-9%-34%—
Gross profitCN¥3.26BCN¥2.77BCN¥3.31BCN¥4.07BCN¥7.40B
EBITDAn/aCN¥1.03BCN¥1.23BCN¥1.79BCN¥4.55B
Net incomeCN¥469MCN¥44.1M-CN¥357MCN¥307MCN¥1.43B
Free cash flowCN¥1.73BCN¥1.75BCN¥847MCN¥1.23BCN¥776M
Capital expenditureCN¥249MCN¥285MCN¥363MCN¥702MCN¥948M
Total debtCN¥1.54BCN¥2.68BCN¥3.66BCN¥4.29BCN¥6.25B

Quarterly statements and history in the cockpit →

Dian Diagnostics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%VIJAYAEMEISPSNLSNDAAMBEA603882WGSAGARWALEYEAGLTDOCNEO4544AZTAUSPH1833ALIF-BLMRICLARIADUSDIA300244.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Dian Diagnostics is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%25×50×75×VIJAYAAMBEA603882WGSAGARWALEYEAGLNEO4544AZTAUSPH1833LMRICLARIADUSDIA300244.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dian Diagnostics is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%VIJAYAEMEISAMBEA603882AGARWALEYETDOC4544AZTAUSPH1833ALIF-BCLARIADUSDIA300244.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dian Diagnostics is the large dot.

Dian Diagnostics competitors and peer comparison

Head to head with its named competitors (300244.SZ vs 603882.SS vs 9860.HK vs LH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Dian Diagnostics 300244.SZ$1.70B+1%-5%9%21.8×0.3%
Guangzhou Kingmed Diagnostics 603882.SS$1.86B+5%-3%7%29.9×5.4%
ADICON 9860.HK$393M+5%+1%4%24.6×12.3%
Labcorp LH$30.1B+44%+6%11%19.3×14.5%

How Dian Diagnostics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dian Diagnostics against its 20 peers (data as of 18 Nov 2026)
Measure300244.SZPeer medianRank in peer set
1-month return-13.3%+1.6%3rd lowest of 21
6-month return+0.8%+19.1%6th lowest of 21
Distance from 52-week high-43.3%-22.4%3rd lowest of 21
Revenue growth (TTM)-5.3%+9.2%lowest of 21
Operating margin8.6%3.2%7th highest of 21
Forward P/E21.8×33.8×6th cheapest of 17
Growth the price implies (Req g, 7 yrs)0.3%8.5%2nd least demanding of 15
Growth delivered (Del g)-1.1%+10.8%3rd lowest of 15
Hurdle (Req g minus delivered)+1.3 pp+7.0 pp6th least demanding of 15
ROIC minus cost of capital+0.4 pp-4.4 pp6th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%21.8×0.3%-1.1%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%63.0×40.4%+16.7%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%n/a21.2%+8.5%
Personalis PSNLUnited States$1.62B+88%+17%-157%n/an/an/a
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%n/an/an/a
Ambea AMBEA.STSweden$1.59B+28%+11%9%15.2×1.1%+7.7%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%29.9×5.4%-6.1%
GeneDx WGSUnited States$1.56B+16%+15%-14%54.2×n/an/a
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%77.1×43.0%+26.9%
agilon health AGLUnited States$1.52B+12%+2%-2%34.1×n/an/a
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%n/a-6.4%+18.3%
NeoGenomics NEOUnited States$1.98B+72%+11%-6%53.5×n/an/a
H.U.Group 4544.TJapan$1.44B+24%+1%3%39.9×9.7%+2.1%
Azenta AZTAUnited States$2.03B+162%+5%-2%83.2×38.0%+3.9%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%29.4×18.8%+13.0%
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
AddLife ALIF-B.STSweden$2.13B+15%+2%8%39.0×21.1%+14.6%
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Addus HomeCare ADUSUnited States$2.25B+29%+12%11%16.2×4.0%+13.2%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%

Questions

Who are Dian Diagnostics's main competitors?
Named competitors: Guangzhou Kingmed Diagnostics (603882.SS), Adicon Holdings (9860.HK), LabCorp (LH). The cockpit's measured peer set (industry) also includes Vijaya Diagnostic Centre (VIJAYA.NS), Emeis (EMEIS.PA), Personalis (PSNL), Sonida Senior Living (SNDA), Ambea (AMBEA.ST), Guangzhou Kingmed Diagnostics (603882.SS).
Is Dian Diagnostics expensive compared with its peers?
On forward p/e it trades at 21.8× against a peer median of 33.8×, 6th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Dian Diagnostics stock performed?
Over six months to 18 Nov 2026 the shares returned +0.8% against +19.1% for the median peer; over one year +15.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.